Establishes a commission to study maximum allowable costs lists used by payers and pharmaceutical benefit managers.

The bill establishes a special commission to investigate the use of maximum allowable costs lists by payers and pharmaceutical benefit managers. These lists determine the maximum amount health plans will pay for certain prescription drugs. The commission will review current practices, industry-wide standardization, and transparency in developing and using these lists.

Establishes a commission to study maximum allowable costs lists used by payers and pharmaceutical benefit managers.

The bill establishes a special commission to investigate the use of maximum allowable costs lists by payers and pharmaceutical benefit managers. These lists determine the maximum amount health plans will pay for certain prescription drugs. The commission will review current practices, industry-wide standardization, and transparency in developing and using these lists.